Total Payments
$154,151
2024 Payments
$25,903
Companies
19
Transactions
123
Medicare Patients
681
Medicare Billing
$99,025
Payment Breakdown by Category
Consulting$112,313 (72.9%)
Research$19,694 (12.8%)
Other$10,890 (7.1%)
Travel$7,619 (4.9%)
Food & Beverage$3,623 (2.4%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,313 | 39 | 72.9% |
| Unspecified | $19,694 | 18 | 12.8% |
| Travel and Lodging | $7,619 | 11 | 4.9% |
| Honoraria | $5,680 | 2 | 3.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,095 | 2 | 2.7% |
| Food and Beverage | $3,623 | 38 | 2.4% |
| Long term medical supply or device loan | $1,115 | 12 | 0.7% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$134,456
105 transactions
Research
$19,694
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72,058 | 47 | $0 (2024) |
| PFIZER INC. | $21,351 | 15 | $0 (2024) |
| Myocardial Solutions, Inc. | $11,294 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $9,259 | 6 | $0 (2024) |
| Lilly USA, LLC | $8,050 | 4 | $0 (2020) |
| Eli Lilly and Company | $6,400 | 1 | $0 (2023) |
| Seagen Inc. | $6,139 | 12 | $0 (2020) |
| WHITEHALL INTERNATIONAL INC | $3,700 | 1 | $0 (2024) |
| Roche Diagnostics Corporation | $3,603 | 3 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $3,558 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,903 | 19 | PFIZER INC. ($11,345) |
| 2023 | $55,478 | 28 | NOVARTIS PHARMACEUTICALS CORPORATION ($27,374) |
| 2022 | $41,691 | 20 | Novartis Pharmaceuticals Corporation ($27,686) |
| 2021 | $5,274 | 11 | Novartis Pharmaceuticals Corporation ($5,262) |
| 2020 | $19,287 | 22 | Lilly USA, LLC ($8,050) |
| 2019 | $6,052 | 20 | Novartis Pharmaceuticals Corporation ($3,204) |
| 2018 | $465.58 | 3 | Novartis Pharma AG ($335.35) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $70.26 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/09/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,750.00 | General |
| 09/21/2024 | Myocardial Solutions, Inc. | — | Food and Beverage | In-kind items and services | $245.43 | General |
| 09/10/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 08/24/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $97.01 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $47.51 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $191.75 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $718.30 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 06/19/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.64 | General |
| 06/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2024 | Myocardial Solutions, Inc. | — | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| 03/20/2024 | WHITEHALL INTERNATIONAL INC | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,700.00 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $96.83 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $945.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | AstraZeneca UK Limited | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/06/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $115.40 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: Oncology | ||||||
| 11/30/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $8,150.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $6,154 | 1 |
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,904 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,794 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,192 | 4 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $718.30 | 1 |
| BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC | Novartis Pharmaceuticals Corporation | $396.11 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR KISQALI RESEARCH | Novartis Pharmaceuticals Corporation | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 198 | 285 | $85,467 | $24,409 |
| 2022 | 5 | 202 | 305 | $93,742 | $25,666 |
| 2021 | 3 | 130 | 229 | $79,928 | $23,309 |
| 2020 | 5 | 151 | 292 | $95,529 | $25,640 |
Total Patients
681
Total Services
1,111
Medicare Billing
$99,025
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 58 | 84 | $28,896 | $7,875 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 95 | $24,225 | $6,448 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 45 | $11,250 | $4,138 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $13,720 | $3,700 | 27.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 17 | 17 | $4,624 | $1,498 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 16 | $2,752 | $750.90 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 58 | 85 | $29,240 | $7,733 | 26.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 83 | $20,750 | $6,467 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 56 | 80 | $20,400 | $5,491 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $17,640 | $4,347 | 24.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 21 | 21 | $5,712 | $1,628 | 28.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 83 | 157 | $54,008 | $15,284 | 28.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $16,170 | $4,774 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 39 | $9,750 | $3,251 | 33.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 48 | 116 | $39,904 | $9,651 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 103 | $25,750 | $7,834 | 30.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 33 | 33 | $16,216 | $4,224 | 26.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 27 | 27 | $7,344 | $2,136 | 29.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $6,315 | $1,796 | 28.4% |
About Dr. Susan Dent, MD
Dr. Susan Dent, MD is a Hematology & Oncology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/01/2018. The National Provider Identifier (NPI) number assigned to this provider is 1912482498.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Dent, MD has received a total of $154,151 in payments from pharmaceutical and medical device companies, with $25,903 received in 2024. These payments were reported across 123 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($112,313).
As a Medicare-enrolled provider, Dent has provided services to 681 Medicare beneficiaries, totaling 1,111 services with total Medicare billing of $99,025. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Rochester, NY
- Active Since 10/01/2018
- Last Updated 10/02/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912482498
Products in Payments
- KISQALI (Drug) $34,723
- PIQRAY (Drug) $28,044
- IBRANCE (Drug) $21,726
- VERZENIO (Drug) $8,050
- Vitrakvi (Drug) $1,370
- Perjeta (Biological) $1,320
- Orserdu (Drug) $514.07
- LEE011H (Drug) $335.35
- KEYTRUDA (Biological) $181.19
- ENHERTU (Biological) $135.00
- Enhertu (Drug) $25.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028